ALX-210-743-C200

antibody from Enzo Life Sciences

Targeting: TNFRSF10B CD262, DR5, KILLER, TRAIL-R2, TRAILR2, TRICK2A, TRICKB

Western blot (Data presented on provider website)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Antibody Data

Product number

ALX-210-743-C200

Provider

Enzo Life Sciences

Proper citation

Enzo Life Sciences Cat#ALX-210-743-C200, RRID:AB_2052727

Product name

TRAIL-R2 polyclonal antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

Epitope-affinity purified IgG.

Reactivity

Human, Mouse

Host

Goat

Vial size

200 μg

Storage

-20°C

Handling

For maximum product recovery after thawing, centrifuge the vial before opening the cap. Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20¡C.

References

Submitted references

Death receptor 5 signaling promotes hepatocyte lipoapoptosis.

Cazanave SC, Mott JL, Bronk SF, Werneburg NW, Fingas CD, Meng XW, Finnberg N, El-Deiry WS, Kaufmann SH, Gores GJ
The Journal of biological chemistry 2011 Nov 11;286(45):39336-48

---

Importance of TNF-related apoptosis-inducing ligand in pathogenesis of interstitial cystitis.

Kutlu O, Akkaya E, Koksal IT, Bassorgun IC, Ciftcioglu MA, Sanlioglu S, Kukul E
International urology and nephrology 2010 Jun;42(2):393-9

---

Lack of death receptor 4 (DR4) expression through gene promoter methylation in gastric carcinoma.

Lee KH, Lim SW, Kim HG, Kim DY, Ryu SY, Joo JK, Kim JC, Lee JH
Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie 2009 Jul;394(4):661-70

---

High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas.

Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balci MK, Omer A, Griffith TS, Sanlioglu S
Pancreas 2008 May;36(4):385-93

---

Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.

Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H
Cell death and differentiation 2004 Jul;11 Suppl 1:S86-96

---

Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5.

Jin TG, Kurakin A, Benhaga N, Abe K, Mohseni M, Sandra F, Song K, Kay BK, Khosravi-Far R
The Journal of biological chemistry 2004 Dec 31;279(53):55594-601

---

Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis.

Higuchi H, Yoon JH, Grambihler A, Werneburg N, Bronk SF, Gores GJ
The Journal of biological chemistry 2003 Jan 3;278(1):454-61

---

The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis.

Higuchi H, Bronk SF, Takikawa Y, Werneburg N, Takimoto R, El-Deiry W, Gores GJ
The Journal of biological chemistry 2001 Oct 19;276(42):38610-8

---

Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy.

Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, Rehemtulla A
Proceedings of the National Academy of Sciences of the United States of America 2000 Feb 15;97(4):1754-9

Immunocytochemistry

Supportive validation

Submitted by

Enzo Life Sciences (provider)

Main image

Experimental details

Specificity of PAb to TRAIL-R2. Lane 1: TRAIL-R3:Fc. Lane 2: TRAIL-R2. ALX-210-743 recognizes a band of approx. 46kDa of the expected size of the recombinant TRAIL-R2:Fc protein in lane 2 and shows no detectable cross-reactivity to TRAIL-R3:Fc in lane 1.